Bacterium Development Immune Response Protein 
Drug Discovery World
JULY 29, 2022
A team led by researchers at HMS and the Broad has just accomplished the rare feat of connecting those dots for one important gut bacterium. The usual suspects for triggering an immune response would be a protein or a sugar,” said Clardy. They also confirmed that the lipid helps maintain immune homeostasis.
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 6, 2020
Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. Graves explained the gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues.
pharmaphorum
JULY 14, 2021
The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range. The post Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar appeared first on.
The Pharma Data
MAY 31, 2022
billion in potential development milestones Proposed acquisition provides access to next-generation 24-valent pneumococcal vaccine candidate in phase II development and highly innovative, MAPS TM technology Supports development of a strong portfolio of innovative vaccines and specialty medicines. GSK to pay $2.1
The Pharma Data
JUNE 2, 2022
billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion upfront payment and up to $1.2
pharmaphorum
MAY 31, 2022
billion in potential development milestones, to get its hands on the ASP3772 shot, which recently claimed a breakthrough designation from the FDA for the treatment of pneumococcal disease in older adults. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot.
Expert insights. Personalized for you.
52 
Let's personalize your content